PubHawk
December 2005 PMID 16423108

The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.

Nina Buscemi, Ben Vandermeer, Nicola Hooton, Rena Pandya, Lisa Tjosvold, Lisa Hartling, Glen Baker, Terry P Klassen, Sunita Vohra

Download social card

Mentions

13
Peak: 1 in Jul 2020
across 4 sources since Jul 2020

Extended reach

6,653
potential audience

Total likes

66

Video views

1,293

Mentions per month

Jul 2020 – Oct 2025

Where it's discussed

  • Blogs5 articles
  • News4 articles
  • YouTube3 videos
  • X / Twitter1 posts

AI synopsis

What people are saying

The discussion is very brief and straightforward, using phrases like 'a study about melatonin' with little added context or emotional tone. This lack of detailed critique or curiosity shows a neutral, surface-level engagement with the research, highlighting the limited impact and interest in the topic.

AgreementNeither agree nor disagree

The discussion does not clearly express agreement or disagreement with the publication, suggesting a neutral stance.

InterestNeutral interest

The post shows minimal curiosity or engagement with the research topic, indicated by the simple acknowledgment.

EngagementNeutral engagement

There is little depth of discussion or critical analysis, reflecting low engagement with the study’s findings or implications.

ImpactNeutral impact

The comment has negligible influence on the broader conversation, merely acknowledging the existence of the study without further elaboration.

Abstract in brief

  • The review analyzed multiple studies to assess how effective and safe exogenous melatonin is for treating primary sleep disorders, finding that it may help reduce the time it takes to fall asleep, especially in delayed sleep phase syndrome, with no significant adverse effects reported.
  • Melatonin appears to be less effective for other primary sleep disorders like insomnia when used short-term (up to 4 weeks), and more large-scale research is needed to confirm its overall efficacy.
  • Overall, short-term use of melatonin (up to 3 months) is considered safe, but its benefits for various sleep issues are still under investigation, with promising results mainly for delayed sleep phase syndrome.]
Read the full abstract

Top posts

Most liked on X and Bluesky
repo
@repobrzuszek · X

@frzzz111 https://t.co/PXovbPM4KT tutaj badanie na temat melatoniny, zeby nie bylo, ze sobie wymyslam

Jul 19, 2020 · 5,360 followers View post →

All mentions

repo
@repobrzuszek · X

@frzzz111 https://t.co/PXovbPM4KT tutaj badanie na temat melatoniny, zeby nie bylo, ze sobie wymyslam

Jul 19, 2020 · 5,360 followers View post →